论文部分内容阅读
目的:探讨艾迪注射液联合GP化疗治疗气阴两虚型晚期非小细胞肺癌(NSCLC)患者的疗效及对免疫功能和凝血功能的影响。方法:将2012年10月-2016年9月于医院肿瘤科确诊为NSCLC的84例患者纳入研究并随机分组,对照组42例患者单纯采用GP化疗治疗,观察组42例采用联合艾迪注射液治疗,28天为1周期,均行4个化疗周期。比较两组患者免疫功能及凝血改善情况,比较临床疗效及不良反应情况。结果:对照组血浆中CD4~+、CD3~+、CD4~+/CD8~+水平明显降低,观察组则升高,且高于对照组(P<0.05);对照组部分活化凝血酶原时间(APTT)、凝血酶原时间(PT)水平降低,D-二聚体(D-D)升高,观察组数值更低(P<0.05);两组总缓解率无统计学差异(P>0.05),但观察组临床获益率更高(P<0.05);两组不良反应以骨髓抑制及肝肾功能损伤为主,发生率无统计学差异(P>0.05)。结论:艾迪注射液联合GP化疗治疗气阴两虚型晚期NSCLC效果显著,可改善免疫功能,纠正高凝状态,值得推广应用。
Objective: To investigate the therapeutic effect of Aidi Injection combined with GP chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC) of deficiency of both qi and yin and its influence on immune function and coagulation function. Methods: Eighty-four patients diagnosed as NSCLC from Department of Oncology in our hospital from October 2012 to September 2016 were enrolled and randomized. In the control group, 42 patients were treated with GP chemotherapy alone. In the observation group, 42 cases were treated with combination of Aidi Injection Treatment, 28 days for a cycle, all 4 cycles of chemotherapy. The immune function and coagulation improvement were compared between the two groups, and the clinical efficacy and adverse reactions were compared. Results: The levels of CD4 ~ +, CD3 ~ + and CD4 ~ + / CD8 ~ + in the control group were significantly lower than those in the control group (P <0.05) (P <0.05). The total remission rate of two groups had no significant difference (P> 0.05), but the level of APTT, PT, PTD increased, , But the observation group had a higher clinical benefit rate (P <0.05). Adverse reactions of the two groups were mainly bone marrow suppression and liver and renal dysfunction, with no significant difference (P> 0.05). Conclusion: Aidi injection combined with GP chemotherapy in the treatment of advanced NSCLC with qi and yin deficiency can improve the immune function and correct the hypercoagulable state, which is worth popularizing and applying.